Classification of Interstitial Lung Diseases and Interstitial Lung Diseases with Etiology of Covid-19

Abstract

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the publication of the new classification of idiopathic interstitial cases of pneumonia, according to which there are three groups: major, rare, and unclassified. The novelty of the new classification comes from the fact that difficult-to-classify entities can be treated according to the disease behaviour classification. Idiopathic pulmonary fibrosis is the most lethal of the interstitial lung diseases and presents high heterogeneity in clinical behavior. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease (COVID-19) dominated the year 2020. Initial reports of the long-term sequelae of COVID-19 include manifestations and exacerbations of interstitial lung disease (ILD), underscoring a pressing need for a better understanding of this group of diseases. The year 2020 brought significant scientific advances in our understanding of the pathogenesis, diagnosis, and treatment of ILD in idiopathic pulmonary fibrosis (IPF) ILD as well as non-IPF ILD.